Intraperitoneal paclitaxel for gastric cancer with peritoneal metastasis

Peritoneal seeding is the most prevalent and grave form of metastatic gastric cancer (GC), and is a poor prognostic factor that is unresponsive to conventional systemic chemotherapy.Peritoneal metastasis (PM) in GC can be treated using several methods, including systemic chemotherapy, intraperitoneal (IP) chemotherapy, and cytoreductive surgery with hyperthermic IP chemotherapy for treating PM in GC.Diverse treatment outcomes of IP chemotherapy for GC with PM have been reported.Therefore, comprehensive therapeutic approaches are required to improve the survival of patients with PM.Recent reports have highlighted several favorable outcomes of the use of simultaneous IP and systemic chemotherapy, especially the use of paclitaxel as a chemotherapeutic agent in the treatment of peritoneal seeding in GC.Additionally, laparoscopic surgery may play a role in the treatment of peritoneal seeding, while innovative strategies, such as pressurized IP aerosol chemotherapy and new materials for IP chemotherapy, present promising strategies for addressing this challenging disease.